Prostate cancer has moved on. The focus used to be on diagnosing this cancer at an early stage. Now that testing is common and so many early cancers are being found, the focus has shifted to trying to prevent these early cancers from developing into advanced disease. Read the article here.
The number of new cases of metastatic prostate cancer climbed 72 percent in the past decade from 2004 to 2013, reports a new Northwestern Medicine study. The report considers whether a recent trend of fewer men being screened may be contributing to the rise, or whether the disease has become more aggressive—or both. Read the article here.
Hacking, the unauthorized access to data, is common these days. There are no federal requirements for cybersecurity standards on hospital equipment, which means once these machines are on a hospital’s network – and there are thousands in every hospital. Billy Rios, a cybersecurity expert, says most are easily hacked. Settings and critical information can be changed. Read the article here.
November 2014 Awareness Night – 20th Anniversary Celebration Watch this video of our 20th anniversary celebration: A bit of history from our founding as Man to Man to our joining the Prostate Cancer Canada Network Congratulatory messages from the medical community Our position on PSA testing as presented by PCC’s President and CEO Rocco Rossi CLICK ON THE ARROW TO START THE VIDEO The Complete Presentation 54:38 minutes
Scientists at Lawson Health Research Institute in London are the first in Canada to capture prostate cancer images using a new molecule. Known as a Prostate Specific Membrane Antigen (PSMA) probe, the new molecule is used in Positron Emissions Tomography (PET) scans. The probe targets PSMA, a unique molecule on prostate cancer cells, to provide highly specific images for better diagnosis and management of patient disease. Read the article here.
In 2012, there were 21,105 new cases of prostate cancer diagnosed, representing 23.4% of all new cancer cases among men. Overall, prostate cancer accounted for 9.5% (3,708) of all cancer deaths among men in 2012. The age-standardized incidence rate of prostate cancer has declined by an average of 3.8% per year since 2006. The annual rate of deaths due to prostate cancer has also fallen. From 1995 to 2012, the age-standardized prostate cancer mortality rate decreased by an average of 2.9% per year, a 40.9% decline over this period. Men who were diagnosed with prostate cancer in 2012 tended to …
Oxford University scientists have started a clinical trial to test a new vaccine against prostate cancer and are looking for volunteers to take part. The first four participants have already received this experimental vaccine at the Churchill Hospital in Oxford, and the second trial site has just been opened at the Royal Hallamshire Hospital in Sheffield. Read the article.